JP2013505282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505282A5 JP2013505282A5 JP2012530248A JP2012530248A JP2013505282A5 JP 2013505282 A5 JP2013505282 A5 JP 2013505282A5 JP 2012530248 A JP2012530248 A JP 2012530248A JP 2012530248 A JP2012530248 A JP 2012530248A JP 2013505282 A5 JP2013505282 A5 JP 2013505282A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- nicotinic acetylcholine
- levodopa
- acetylcholine receptor
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019082 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 12
- 108010051895 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 12
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 10
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 7
- 229960004502 levodopa Drugs 0.000 claims 7
- 206010061536 Parkinson's disease Diseases 0.000 claims 6
- 230000003281 allosteric Effects 0.000 claims 6
- 230000000051 modifying Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000001187 Dyskinesias Diseases 0.000 claims 4
- 102100001420 MAOB Human genes 0.000 claims 4
- 101710040126 MAOB Proteins 0.000 claims 4
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 4
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 101710002904 tyrDC Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
Claims (12)
- ニコチン性アセチルコリン受容体アルファ７アゴニストまたはニコチン性アセチルコリン受容体アルファ７ポジティブアロステリックモジュレーターを有効成分として含む、パーキンソン病におけるドーパミンアゴニスト治療と関連するジスキネジアの処置、予防または進行遅延に使用するための薬剤。
- ニコチン性アセチルコリン受容体アルファ７アゴニストを有効成分として含む、パーキンソン病におけるドーパミンアゴニスト治療と関連するジスキネジアの処置、予防または進行遅延に使用するための薬剤。
- 治療がレボドパの投与を含む、請求項１または２に記載の薬剤。
- (ｉ)ドーパミンアゴニストおよび(ii)α７−ｎＡＣｈＲアゴニストまたはα７−ｎＡＣｈＲポジティブアロステリックモジュレーターを有効成分として含むパーキンソン病の処置または進行遅延のための薬剤であって、ここで、ドーパミンアゴニストの１日投与量がα７−ｎＡＣｈＲアゴニストまたはα７−ｎＡＣｈＲポジティブアロステリックモジュレーターの共投与を受けていない対象において同程度のパーキンソン病管理を達成するのに必要な該ドーパミンアゴニストの１日投与量と比較して減少している、薬剤。
- ドーパミンアゴニストがレボドパを含む、請求項４に記載の薬剤。
- ニコチン性アセチルコリン受容体アルファ７アゴニストまたはニコチン性アセチルコリン受容体アルファ７ポジティブアロステリックモジュレーターを含む、パーキンソン病におけるドーパミンアゴニスト治療と関連するジスキネジアを処置、予防または進行遅延するための医薬組成物。
- ニコチン性アセチルコリン受容体アルファ７アゴニストを含む、パーキンソン病におけるドーパミンアゴニスト治療と関連するジスキネジアを処置、予防または進行遅延するための医薬組成物。
- 治療がレボドパの投与を含む、請求項６または７に記載の医薬組成物。
- (Ａ)ニコチン性アセチルコリン受容体アルファ７アゴニストまたはニコチン性アセチルコリン受容体アルファ７ポジティブアロステリックモジュレーター；および
(Ｂ)レボドパ、レボドパデカルボキシラーゼ阻害剤、カテコール−Ｏ−メチルトランスフェラーゼ阻害剤、モノアミンオキシダーゼＢ阻害剤またはドーパミン受容体アゴニストの少なくとも１種
を含む、組合せ剤。 - (Ａ)ニコチン性アセチルコリン受容体アルファ７アゴニスト；および(Ｂ)レボドパ、レボドパデカルボキシラーゼ阻害剤、カテコール−Ｏ−メチルトランスフェラーゼ阻害剤、モノアミンオキシダーゼＢ阻害剤またはドーパミン受容体アゴニストの少なくとも１種
を含む、組合せ剤。 - (Ａ)ニコチン性アセチルコリン受容体アルファ７アゴニストまたはニコチン性アセチルコリン受容体アルファ７ポジティブアロステリックモジュレーター；および
(Ｂ)レボドパ、レボドパデカルボキシラーゼ阻害剤、カテコール−Ｏ−メチルトランスフェラーゼ阻害剤、モノアミンオキシダーゼＢ阻害剤またはドーパミン受容体アゴニストの少なくとも１種
を含む、医薬組成物。 - (Ａ)ニコチン性アセチルコリン受容体アルファ７アゴニスト；および(Ｂ)レボドパ、レボドパデカルボキシラーゼ阻害剤、カテコール−Ｏ−メチルトランスフェラーゼ阻害剤、モノアミンオキシダーゼＢ阻害剤またはドーパミン受容体アゴニストの少なくとも１種を含む、医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24465809P | 2009-09-22 | 2009-09-22 | |
| US61/244,658 | 2009-09-22 | ||
| PCT/EP2010/063946 WO2011036167A1 (en) | 2009-09-22 | 2010-09-22 | Use of nicotinic acetylcholine receptor alpha 7 activators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015237921A Division JP2016104743A (ja) | 2009-09-22 | 2015-12-04 | ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013505282A JP2013505282A (ja) | 2013-02-14 |
| JP2013505282A5 true JP2013505282A5 (ja) | 2013-11-07 |
| JP6178074B2 JP6178074B2 (ja) | 2017-08-09 |
Family
ID=42990156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530248A Active JP6178074B2 (ja) | 2009-09-22 | 2010-09-22 | ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 |
| JP2015237921A Withdrawn JP2016104743A (ja) | 2009-09-22 | 2015-12-04 | ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015237921A Withdrawn JP2016104743A (ja) | 2009-09-22 | 2015-12-04 | ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10537539B2 (ja) |
| EP (1) | EP2480228B1 (ja) |
| JP (2) | JP6178074B2 (ja) |
| KR (1) | KR20120068878A (ja) |
| CN (2) | CN102573830A (ja) |
| AU (1) | AU2010299967B2 (ja) |
| BR (1) | BR112012006346A2 (ja) |
| CA (1) | CA2774801C (ja) |
| CL (1) | CL2012000702A1 (ja) |
| EA (1) | EA036742B1 (ja) |
| ES (1) | ES2614930T3 (ja) |
| IL (1) | IL218299A (ja) |
| JO (1) | JO3250B1 (ja) |
| MA (1) | MA33590B1 (ja) |
| MX (1) | MX359011B (ja) |
| NZ (1) | NZ598316A (ja) |
| SG (1) | SG178832A1 (ja) |
| TN (1) | TN2012000082A1 (ja) |
| TW (1) | TWI558398B (ja) |
| WO (1) | WO2011036167A1 (ja) |
| ZA (1) | ZA201201066B (ja) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| TWI558398B (zh) * | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| EP2571874B1 (en) | 2010-05-17 | 2016-03-30 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| MX2013008704A (es) * | 2011-01-27 | 2013-08-21 | Novartis Ag | Uso de activadores del receptor de acetil-colina nicotinico alfa-7. |
| JP5865397B2 (ja) | 2011-02-03 | 2016-02-17 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | α７ｎＡＣｈＲのモジュレータとして使用されるピロール誘導体 |
| LT2678327T (lt) | 2011-02-23 | 2016-11-25 | Lupin Limited | Heteroarilo dariniai kaip nachr alpha7 moduliatoriai |
| MX2013010698A (es) * | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
| SG193387A1 (en) | 2011-03-31 | 2013-10-30 | Lupin Ltd | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| US8946432B2 (en) | 2011-07-05 | 2015-02-03 | Lupin Limited | Biaryl derivatives as nAChR modulators |
| AU2012324458B2 (en) * | 2011-10-20 | 2016-05-19 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| WO2013132380A1 (en) | 2012-03-06 | 2013-09-12 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
| EP2945936A1 (en) | 2012-11-12 | 2015-11-25 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| KR101879919B1 (ko) * | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도 |
| ES2883232T3 (es) * | 2013-01-15 | 2021-12-07 | Novartis Ag | Uso de agonistas del receptor nicotínico de acetilcolina alfa 7 |
| EP2945941B1 (en) | 2013-01-16 | 2016-12-07 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| EP2970180A1 (en) | 2013-03-13 | 2016-01-20 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| US9504680B2 (en) | 2013-06-17 | 2016-11-29 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| AU2014296255B2 (en) | 2013-07-31 | 2017-08-03 | Novartis Ag | 1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions |
| WO2015168616A1 (en) * | 2014-05-02 | 2015-11-05 | Abbvie Inc. | Neuronal nicotinic agonists and methods of use |
| EP3191508B1 (en) | 2014-09-09 | 2020-11-04 | Boehringer Ingelheim Animal Health USA Inc. | Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays |
| EP3623371A1 (en) | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| WO2016201096A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
| US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
| WO2017069980A1 (en) * | 2015-10-20 | 2017-04-27 | Forum Pharmaceuticals, Inc. | Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors |
| EP3661509A4 (en) | 2017-08-04 | 2021-01-13 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE |
| KR20210135241A (ko) | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| CN113677344A (zh) | 2019-02-06 | 2021-11-19 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566368B2 (en) | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| US5990168A (en) | 1996-04-18 | 1999-11-23 | Alberta Cancer Board | Methods and compositions for the treatment of ataxia telangiectasia |
| US7214686B2 (en) * | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US6908631B1 (en) * | 1997-12-01 | 2005-06-21 | Nicogen, Inc. | Therapeutic and diagnostic methods dependent on CYP2A enzymes |
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| CA2393437C (en) | 1998-12-16 | 2009-12-15 | University Of South Florida | Exo-s-mecamylamine formulation and use in treatment |
| FR2804430B1 (fr) | 2000-01-28 | 2002-03-22 | Sanofi Synthelabo | Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
| SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
| DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| US20050245567A1 (en) | 2002-08-14 | 2005-11-03 | Dan Peters | Novel quinuclidine derivatives and their use |
| EP1531820A1 (en) | 2002-08-30 | 2005-05-25 | Memory Pharmaceuticals Corporation | Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| PL210065B1 (pl) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków |
| EP1592710A2 (en) | 2003-02-14 | 2005-11-09 | Memory Pharmaceutical Corporation | Macaque alpha-7 nicotinic acetylcholine receptor and methods of use thereof |
| BRPI0407216A (pt) | 2003-02-27 | 2006-01-24 | Neurosearch As | Derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| WO2005044267A1 (en) | 2003-10-31 | 2005-05-19 | Astrazeneca Ab | Alkynes ii |
| CN1871001A (zh) | 2003-10-31 | 2006-11-29 | 阿斯利康(瑞典)有限公司 | 炔烃ⅲ |
| EP1677789A1 (en) | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes i |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| JP4824578B2 (ja) | 2003-12-22 | 2011-11-30 | メモリー・ファーマシューティカルズ・コーポレイション | インドール類、１，２−ベンズイソオキサゾール類、および１，２−ベンゾイソチアゾール類、ならびにそれらの製造と使用 |
| EP1713810B1 (en) | 2004-02-04 | 2010-12-29 | NeuroSearch A/S | Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands |
| BRPI0506890A (pt) | 2004-02-04 | 2007-07-17 | Neurosearch As | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo |
| US20070149547A1 (en) | 2004-02-12 | 2007-06-28 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
| KR101176670B1 (ko) | 2004-03-25 | 2012-08-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도 |
| EP1742944B1 (en) | 2004-04-22 | 2010-11-10 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| WO2005111038A2 (en) | 2004-05-07 | 2005-11-24 | Memory Pharmaceuticals Corporation | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| JP2007538046A (ja) | 2004-05-19 | 2007-12-27 | ノイロサーチ アクティーゼルスカブ | 新規なアザビシクロアリール誘導体 |
| GB0412019D0 (en) | 2004-05-28 | 2004-06-30 | Novartis Ag | Organic compounds |
| PE20060437A1 (es) * | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| AU2005293510A1 (en) | 2004-10-15 | 2006-04-20 | Neurosearch A/S | Novel azabicyclic aryl derivatives and their medical use |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| WO2006051407A1 (en) | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
| WO2006051394A1 (en) * | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
| MX2007003331A (es) | 2004-11-30 | 2007-06-05 | Neurosearch As | Nuevos derivados de arilo diazabiciclico. |
| JP2008523058A (ja) | 2004-12-10 | 2008-07-03 | アボット・ラボラトリーズ | 縮合ビシクロ複素環置換キヌクリジン誘導体 |
| AU2005319248A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| US20060142349A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| WO2006087306A2 (en) | 2005-02-16 | 2006-08-24 | Neurosearch A/S | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors |
| WO2006103511A1 (en) | 2005-03-31 | 2006-10-05 | Pfizer Products Inc. | Cyclopentapyridine and tetrahydroquinoline derivatives |
| FR2884822B1 (fr) | 2005-04-22 | 2007-06-29 | Aventis Pharma Sa | Derives de triazines, leur preparation et leur application en therapeutique |
| WO2006116407A2 (en) | 2005-04-22 | 2006-11-02 | Cedars-Sinai Medical Center | Compositions and methods for spinocerebellar ataxia |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| US8629163B2 (en) | 2007-10-31 | 2014-01-14 | University Of Kentucky Research Foundation | Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors |
| WO2007038367A1 (en) | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| BRPI0619672A2 (pt) | 2005-11-09 | 2011-10-11 | Memory Pharm Corp | composto, composição farmacêutica, e, uso de um composto |
| JP2009518357A (ja) | 2005-12-06 | 2009-05-07 | ノイロサーチ アクティーゼルスカブ | 新規なジアザ二環式アリール誘導体及びそれらの医学的使用 |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| AR058554A1 (es) | 2005-12-20 | 2008-02-13 | Novartis Ag | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. |
| WO2007085036A1 (en) | 2006-01-26 | 2007-08-02 | Medizinische Universität Wien | Treatment of friedreich' s ataxia |
| US7662965B2 (en) | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| JP2009526776A (ja) | 2006-02-14 | 2009-07-23 | ノイロサーチ アクティーゼルスカブ | 新規なジアザビシクロアルカン誘導体及びその医療上の使用 |
| JP2010519171A (ja) | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | ５−ｈｔ６受容体親和性を有する化合物 |
| DK1991225T3 (da) | 2006-02-22 | 2013-12-16 | Apotex Technologies Inc | Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern |
| RU2008138532A (ru) * | 2006-03-27 | 2010-04-10 | Пфайзер Продактс Инк. (Us) | Стандарты варениклина и контроль примесей |
| TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| JP2009537600A (ja) | 2006-05-23 | 2009-10-29 | ノイロサーチ アクティーゼルスカブ | 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用 |
| JP2009537599A (ja) | 2006-05-23 | 2009-10-29 | ノイロサーチ アクティーゼルスカブ | 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用 |
| AU2007267175A1 (en) | 2006-05-30 | 2007-12-06 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| EP2029595B1 (en) | 2006-05-30 | 2011-09-21 | NeuroSearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use |
| EP2044038B1 (en) | 2006-06-06 | 2014-07-02 | Cornerstone Therapeutics Inc. | Novel piperazines, pharmaceutical compositions and methods of use thereof |
| WO2007149163A2 (en) | 2006-06-16 | 2007-12-27 | University Of Kentucky | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors |
| EP2044029B1 (en) | 2006-07-14 | 2011-01-26 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
| JP2010519226A (ja) | 2007-02-16 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | ５−ｈｔ６受容体親和性を有する６’位置換インドール及びインダゾール誘導体 |
| JP2010523587A (ja) | 2007-04-02 | 2010-07-15 | パーキンソンズ インスティテュート | 治療処置の副作用の低減のための方法および組成物 |
| CN101730680A (zh) | 2007-05-24 | 2010-06-09 | 记忆医药公司 | 具有5-ht6受体亲和力的4’取代的化合物 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| CA2695456A1 (en) | 2007-08-15 | 2009-02-19 | Robert Dunn | 3' substituted compounds having 5-ht6 receptor affinity |
| US8114891B2 (en) | 2007-10-01 | 2012-02-14 | Comentis, Inc. | 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof |
| CN101815512B (zh) | 2007-10-04 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | 环丙基芳基酰胺衍生物和其用途 |
| CA2701214C (en) | 2007-10-04 | 2016-08-02 | F. Hoffmann-La Roche Ag | Tetrazole-substituted aryl amide derivatives and uses thereof |
| WO2009066107A1 (en) | 2007-11-21 | 2009-05-28 | Astrazeneca Ab | Use of a nicotinic receptor agonist |
| CA2714232A1 (en) | 2008-02-05 | 2009-08-13 | Pfizer Inc. | Pyridinyl amides for the treatment of cns and metabolic disorders |
| WO2009105585A2 (en) | 2008-02-19 | 2009-08-27 | Myocept Inc. | Postsynaptically targeted chemodenervation agents and their methods of use |
| US9463190B2 (en) | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
| JP2011516599A (ja) | 2008-04-17 | 2011-05-26 | グラクソ グループ リミテッド | ニコチン性アセチルコリン受容体サブタイプα７のモジュレーターとしてのインドール類 |
| WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| WO2009143019A2 (en) | 2008-05-23 | 2009-11-26 | University Of South Florida | Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity |
| US20100016297A1 (en) | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| US20100056531A1 (en) | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100056491A1 (en) | 2008-08-29 | 2010-03-04 | Memory Pharmaceuticals Corporation | 4'-amino cyclic compounds having 5-ht6 receptor affinity |
| JP5425915B2 (ja) | 2008-10-13 | 2014-02-26 | エフ．ホフマン−ラ ロシュ アーゲー | 二環５−（トリフルオロメトキシ）−１ｈ−３−インダゾールカルボン酸アミドの合成におけるインダゾール中間体のジアゾニウムフリーの製造方法 |
| JP5657556B2 (ja) | 2008-11-11 | 2015-01-21 | ターガセプト，インコーポレイテッド | α７選択的リガンドを用いる治療 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| EP2442810A4 (en) | 2009-06-17 | 2012-11-28 | Targacept Inc | INVERSION OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS |
| CN102573842A (zh) | 2009-07-23 | 2012-07-11 | 诺瓦提斯公司 | 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途 |
| TWI558398B (zh) * | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
-
2010
- 2010-09-21 TW TW099132066A patent/TWI558398B/zh active
- 2010-09-21 JO JOP/2010/0321A patent/JO3250B1/ar active
- 2010-09-22 EA EA201200507A patent/EA036742B1/ru unknown
- 2010-09-22 CA CA2774801A patent/CA2774801C/en active Active
- 2010-09-22 CN CN2010800422554A patent/CN102573830A/zh active Pending
- 2010-09-22 AU AU2010299967A patent/AU2010299967B2/en active Active
- 2010-09-22 SG SG2012010724A patent/SG178832A1/en unknown
- 2010-09-22 BR BR112012006346A patent/BR112012006346A2/pt not_active Application Discontinuation
- 2010-09-22 JP JP2012530248A patent/JP6178074B2/ja active Active
- 2010-09-22 US US13/393,351 patent/US10537539B2/en active Active
- 2010-09-22 CN CN201910302304.6A patent/CN110051670A/zh active Pending
- 2010-09-22 EP EP10762629.3A patent/EP2480228B1/en active Active
- 2010-09-22 ES ES10762629.3T patent/ES2614930T3/es active Active
- 2010-09-22 NZ NZ598316A patent/NZ598316A/xx unknown
- 2010-09-22 MX MX2012003413A patent/MX359011B/es active IP Right Grant
- 2010-09-22 KR KR1020127007287A patent/KR20120068878A/ko active Search and Examination
- 2010-09-22 WO PCT/EP2010/063946 patent/WO2011036167A1/en active Application Filing
-
2012
- 2012-02-14 ZA ZA2012/01066A patent/ZA201201066B/en unknown
- 2012-02-17 TN TNP2012000082A patent/TN2012000082A1/en unknown
- 2012-02-23 IL IL218299A patent/IL218299A/en active IP Right Grant
- 2012-03-16 MA MA34696A patent/MA33590B1/fr unknown
- 2012-03-21 CL CL2012000702A patent/CL2012000702A1/es unknown
-
2015
- 2015-12-04 JP JP2015237921A patent/JP2016104743A/ja not_active Withdrawn
-
2019
- 2019-12-04 US US16/703,501 patent/US11096916B2/en active Active
-
2021
- 2021-07-16 US US17/378,136 patent/US20210338621A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505282A5 (ja) | ||
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| JP2015515475A5 (ja) | ||
| MX2009005339A (es) | Suspensiones analgesicas de liberacion modificada. | |
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| JP2015523407A5 (ja) | ||
| MX336657B (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2013541583A5 (ja) | ||
| WO2008067991A3 (en) | Skin-friendly drug complexes for transdermal administration | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| JP2013536837A5 (ja) | ||
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| JP2016505050A5 (ja) | ||
| JP2011500589A5 (ja) | ||
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. |